AZD0865

DRUG2 trials

Sponsors

AstraZeneca

Conditions

GERD With Erosive EsophagitisGERD Without Erosive Esophagitis

Phase 2

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

CompletedNCT00206284

AstraZenecaGERD Without Erosive Esophagitis

Start: 2004-05-31End: 2005-04-30Target: 1400Updated: 2013-01-04

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

CompletedNCT00206245

AstraZenecaGERD With Erosive Esophagitis

Start: 2004-05-31End: 2005-03-31Target: 1400Updated: 2013-01-04

Related Papers

Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression

Alimentary Pharmacology & Therapeutics2014-07-158 citations

Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy

Gut2013-07-0533 citations